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Introduction
In recent years, numerous studies concerning the association of drug-metabolizing enzyme polymorphism with autoimmune diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), dermatitis herpetiformis (DH), and mixed connective tissue diseases (MCTD) have been carried out [1] [2] [3] [4] [5] [6] [7] [8] [9] .
The current knowledge on the pathomechanism of autoimmune diseases indicates that many etiological factors may have a genetic background [10] [11] [12] [13] [14] [15] [16] .
In the course of systemic sclerosis, several factors suggest the involvement of a genetic component: a relationship between the disease's prevalence and the gender; familial case reports; frequent coexistence of autoimmune diseases or immune phenomena in the families of patients suffering from SSc; higher prevalence of the disease in some ethnic groups; as well as the results of investigations on the system of antigen tissue compatibility; association with polymorphism of genes encoding extracellular matrix components, signaling molecules, and cytokines; studies concerning chromosomal fragility phenomenon; and genetically conditioned animal models of this disease [17] [18] [19] . Recently, studies on the association between the prevalence of SSc and the polymorphism of numerous genes have been conducted. In patients from Japan and the Choctaw Indian tribe, single nucleotide polymorphisms (SNP) within the FBN-1 gene were more frequently observed than in controls; however, Wipff et al. did not find similar changes in French and Italian populations [20, 21] . A higher density of CD19 in B lymphocytes (approximately 20%) was reported in patients with SSc, as compared to a general population, whereas a single nucleotide mutation, G499T, in the CD19 receptor was found to indicate a high risk for developing SSc in a Japanese population [22, 23] . Moreover, the polymorphism of genes encoding angiotensin-converting enzyme (ACE) and mutations within the genes encoding receptors for IL-1B, IL-2, and IL-10 were investigated in SSc patients [24] [25] [26] .
Environmental factors have been known to play a crucial role in scleroderma, therefore numerous studies are being performed whose aim is to elucidate the effect of xenobiotics on the occurrence of autoimmune processes leading to SSc development. Many xenobiotics may induce alterations in the chromosomal structure, e.g., drugs, pesticides, fungicides, or substances causing environmental pollution [27] . The studies on etiopathogenesis of autoimmune diseases focus on the impact the genetically conditioned impairment of xenobiotic metabolism may exert. Many enzymes of cytochrome P450, including CYP2D6, play an instrumental role in the oxidation of multiple drugs and in the activation and deactivation of environmental xenobiotics. The knowledge of oxidation polymorphism in the course of SSc may be helpful in choosing more efficient and safer therapy, particularly in the case of a disease involving various organs and treated with drugs belonging to diverse therapeutic groups. The aim of the present work was to assess the genetically determined CYP2D6 polymorphism, one of the izoenzymes of phase I drug metabolism in patients suffering from systemic sclerosis. The usefulness of CYP2D6 genotype study and the prevalence of CYP2D6 gene mutation were determined to evaluate susceptibility to SSc development.
Materials and methods
The study was carried out in 43 patients with SSc diagnosed according to the criteria of the American College of Rheumatology. The group of patients with SSc consisted of 34 women and 9 men (age range 17-76 years, mean 54± 12.94). In 17 patients, diffuse SSc (dSSc) was diagnosed, and 26 patients fulfilled the criteria for limited SSc (lSSc). The patients were treated at the Department of Dermatology and Venereology, Medical University of Lodz. The control group consisted of 129 healthy volunteers (80 women, 49 men) aged 18-73 years (mean age 41.3±15.41). The local Ethics Committee for Scientific Research approved the study, and informed consent was obtained from all patients.
The identification of the CYP2D6 gene alleles (CYP2D6*1, CYP2D6*3, CYP2D6*4) was performed according to the procedure described by Smith et al. [28] .
The application of the PCR-RFLP method allowed two phenotypically distinct oxidation groups of subjects to be isolated: poor metabolizers (PM), which were homozygotes possessing two mutated alleles: CYP2D6*3 and CYP2D6*4; and extensive metabolizers (EM), which were heterozygotes possessing one wild-type allele (CYP2D6*1) and one mutated allele (CYP2D6*3, CYP2D6*4) or homozygotes possessing two wild alleles (CYP2D6*1) in their loci.
The frequency distribution of CYP2D6 genotypes in SSc patients was compared with healthy subjects and analyzed statistically using the χ 2 test alone and with the Yates modification for small groups. The odds ratio (OR) with 95% confidence interval (95% CI) was calculated using the computer program Statistica 6.0.
Results
The frequency distributions of oxidation genotypes determining poor and extensive metabolizers in patients suffering from systemic sclerosis and in the control group were similar: 11.6 and 9.3%, 88.4 and 90.7%, respectively. There were no statistically significant differences in the prevalence of CYP2D6 genotypes determining poor and extensive oxidation between the two groups (P=0.8827) ( Table 1 ). In separating the SSc patients into the two subsets, we did not find any association with oxidation genotype in patients from the dSSc and lSSc groups (P=0.6417; P=0.3524) ( Table 1 ).
The CYP2D6*1/CYP2D6*4 genotype was most frequently found in the group of patients with SSc (67.4%), Table 1 Distribution of genotypes determining poor and extensive oxidation in patients with systemic sclerosis (SSc), diffuse systemic sclerosis (dSSc), limited systemic sclerosis (lSSc), and in controls Table 2 ). The relative risk for developing lSSc and dSSc in particular genotype carriers, expressed as the odds ratio (OR), was statistically significantly higher for subjects with the CYP2D6*1/CYP2D6*4 genotype (OR=3.7, P=0.0023; OR=7.5, P=0.0002) ( Table 2) . Among 86 alleles studied in patients with SSc, the mutated alleles accounted for 47.7%, and the wild one accounted for 52.3%. Among 258 alleles in the control group, the mutated alleles, CYP2D6, accounted for 26%, and the wild ones accounted for 74%. A statistically significant correlation was found between the prevalence of the CYP2D6*4 allele and the risk for developing SSc (OR=2.6; P=0.0002) and also between the prevalence of the CYP2D6*4 allele and the risk for developing lSSc (OR = 2.7; P=0.0015) and dSSc (OR=2.4; P=0.0147) ( Table 3) .
Discussion
The human organism is constantly exposed to harmful exogenous factors (xenobiotics), including drugs and carcinogenic compounds that can induce development of a large number of diseases. The processes of biotransformation in the organisms are multidirectional and xenobiotics can be transformed into active or inactive metabolites through oxidative routes. They can be changed into harmful compounds with a potentially pathogenic action. The enzymatic system of the liver microsomal fraction with cytochrome P450 as its fundamental element is responsible for xenobiotic oxidation. Cytochrome P450 enzymes show genetic polymorphism, which contributes to considerable interindividual differences in drug responses. Studies of the oxidative genotype or phenotype have been performed in order to identify the oxidative polymorphism.
Differences among individuals in drug response due to mutations within the CYP2D6 gene involved in the xenobiotic metabolism, including a number of drugs with a wide therapeutic use, were discovered as early as the Table 2 Frequency distribution of CYP2D6 alleles in the group of patients with systemic sclerosis (SSc), diffuse systemic sclerosis (dSSc), limited systemic sclerosis (lSSc), and in the controls SSc (n=43) lSSc (n=26) dSSc (n=17) n (%)
OR (95% CI) 1970s. Genetically determined oxidative polymorphism can affect not only drug efficacy but can also be a factor predisposing to disease development [29] [30] [31] [32] [33] [34] [35] [36] .
There are few reports in the available literature that concern the role of oxidative polymorphism in autoimmune diseases, however no studies have dealt with the CYP2D6 genotype in the course of systemic sclerosis.
First investigations on the association between the oxidative genotype and autoimmune diseases were conducted in the 1990s. Studies have demonstrated that oxidative polymorphism is not associated with the risk factor for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) development [1, 2, 8] .
In our own studies on the CYP2D6 genotype in SSc, we observed a similar percentage of individuals who were characterized by poor metabolism among SSc patients in comparison with healthy controls. No statistically significant differences in the prevalence of CYP2D6 genotypes for poor and extensive oxidation were found between the groups studied (P=0.8827). The relative risk for developing SSc in particular genotype carriers, expressed as the odds ratio (OR), was statistically significantly higher for subjects with the CYP2D6*1/CYP2D6*4 genotype (OR = 4.8; P<0.001). A relative risk for developing SSc was 2.6-fold higher in CYP2D6*4 allele carriers and was statistically significant (P=0.0002).
A higher prevalence of mutated CYP2D6*4 alleles in patients with SSc suggests the effect of mutation on an increased frequency of two forms of SSc-limited SSc (lSSc) and diffuse SSc (dSSc).
The effect of CYP2D6 gene mutation on the risk of disease development has awakened a lot of interest in researchers. The polymorphism of this gene may be associated with the subjects' predisposition to neurological diseases [29, 36] . The studies carried out by Butler et al. demonstrate a higher risk for development of colorectal cancer (OR=3.34) in women possessing the CYP2D6*1 allele in their genotype, which determines extensive oxidation [35] .
There are reports in the literature presenting the influence of the polymorphism of other cytochrome P450 enzymes on the risk of SSc development. Povey et al. revealed that the CYP2E1*3 allele of cytochrome P450, one of the phase I izoenzymes, was more frequently found in patients with systemic sclerosis who had been exposed to organic solvent (trichloroethylene, trichloroethane) activity as compared to healthy subjects. Such a correlation was not observed in the group of patients with an idiopathic form of SSc [37] . In other investigations also concerning the phase I xenobiotic metabolism, a reduced ability of dapsone and S-mephenitoin hydroxylation was reported in SSc patients, whereas there was no difference in the activity of debrizochin hydroxylase between this group and Table 3 Frequency distribution of particular alleles in the group of patients with systemic sclerosis (SSc), diffuse systemic sclerosis (dSSc), limited systemic sclerosis (lSSc), and in the controls P Statistical significance of the difference (statistically significant differences P<0.05), χ 2 test comparing two groups, C.I. confidence interval, OR odds ratio controls. May et al. evaluated that the relative risk of SSc development was 10-fold higher (P=0.008) in patients with poor metabolism of mephenitoin and dapsone. This complex metabolic impairment may contribute to SSc development, or, on the other hand, the pathological process could be solely responsible for inhibition of selected enzymes metabolizing xenobiotics in some groups of patients [1] . Investigating the distribution of CYP1A1 polymorphisms, von Schmiedeberg et al. did not observe significant differences among SSc patients in comparison to a healthy population [2] .
Genetic factors play a significant role in the etiopathogenesis of systemic sclerosis. Knowledge of the genetically conditioned differences in oxidation processes as well as determination of the prevalence of the main mutations in the cytochrome P450 izoenzyme CYP2D6 gene seems to be of vital clinical importance.
